These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35982335)

  • 1. Efficacy and toxicity of hydroxyurea in mast cell activation syndrome patients refractory to standard medical therapy: retrospective case series.
    Weinstock LB; Brook JB; Molderings GJ
    Naunyn Schmiedebergs Arch Pharmacol; 2022 Nov; 395(11):1441-1447. PubMed ID: 35982335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of hydroxyurea in mast cell activation syndrome.
    Afrin LB
    Exp Hematol Oncol; 2013 Oct; 2(1):28. PubMed ID: 24192267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idiopathic mast cell activation syndrome is more often suspected than diagnosed-A prospective real-life study.
    Buttgereit T; Gu S; Carneiro-Leão L; Gutsche A; Maurer M; Siebenhaar F
    Allergy; 2022 Sep; 77(9):2794-2802. PubMed ID: 35364617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mast Cell Activation Syndrome and Gut Dysfunction: Diagnosis and Management.
    Hamilton MJ
    Curr Gastroenterol Rep; 2024 Apr; 26(4):107-114. PubMed ID: 38353900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient characteristics of suspected mast-cell activation syndrome with sinonasal obstruction: a single institution experience.
    Kim JH; Xi S; Ference EH; Ge M; Liu MM; Wrobel BB
    Int Forum Allergy Rhinol; 2020 Aug; 10(8):996-1000. PubMed ID: 32407593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection. Swiss HIV Cohort Study.
    Rutschmann OT; Vernazza PL; Bucher HC; Opravil M; Ledergerber B; Telenti A; Malinverni R; Bernasconi E; Fagard C; Leduc D; Perrin L; Hirschel B
    AIDS; 2000 Sep; 14(14):2145-51. PubMed ID: 11061656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patients.
    Doyle LA; Sepehr GJ; Hamilton MJ; Akin C; Castells MC; Hornick JL
    Am J Surg Pathol; 2014 Jun; 38(6):832-43. PubMed ID: 24618605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restless legs syndrome is associated with mast cell activation syndrome.
    Weinstock LB; Walters AS; Brook JB; Kaleem Z; Afrin LB; Molderings GJ
    J Clin Sleep Med; 2020 Mar; 16(3):401-408. PubMed ID: 31994488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11β-prostaglandin2α.
    Ravi A; Butterfield J; Weiler CR
    J Allergy Clin Immunol Pract; 2014; 2(6):775-8. PubMed ID: 25439370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mast cell activation syndrome: Myths and realities.
    Zhang S; Bernstein JA
    Allergy Asthma Proc; 2021 May; 42(3):198-204. PubMed ID: 33980332
    [No Abstract]   [Full Text] [Related]  

  • 11. [Idiopathic mast cell activation syndrome].
    van Daele PLA; Hermans MAW; Oude Elberink JHNG; van Wijk RG
    Ned Tijdschr Geneeskd; 2022 Jan; 166():. PubMed ID: 35129899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful mast-cell-targeted treatment of chronic dyspareunia, vaginitis, and dysfunctional uterine bleeding.
    Afrin LB; Dempsey TT; Rosenthal LS; Dorff SR
    J Obstet Gynaecol; 2019 Jul; 39(5):664-669. PubMed ID: 30964355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Some cases of hypermobile Ehlers-Danlos syndrome may be rooted in mast cell activation syndrome.
    Afrin LB
    Am J Med Genet C Semin Med Genet; 2021 Dec; 187(4):466-472. PubMed ID: 34719842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cluster-Analytic Identification of Clinically Meaningful Subtypes in MCAS: The Relevance of Heat and Cold.
    Häder T; Molderings GJ; Klawonn F; Conrad R; Mücke M; Sellin J
    Dig Dis Sci; 2023 Aug; 68(8):3400-3412. PubMed ID: 37029308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mast Cell Activation Syndrome: A Primer for the Gastroenterologist.
    Weinstock LB; Pace LA; Rezaie A; Afrin LB; Molderings GJ
    Dig Dis Sci; 2021 Apr; 66(4):965-982. PubMed ID: 32328892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mast cell activation syndrome as a significant comorbidity in sickle cell disease.
    Afrin LB
    Am J Med Sci; 2014 Dec; 348(6):460-4. PubMed ID: 25171546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus: A systematic review, meta-analysis and meta-regression of randomized controlled trials.
    Nabrdalik K; Skonieczna-Żydecka K; Irlik K; Hendel M; Kwiendacz H; Łoniewski I; Januszkiewicz K; Gumprecht J; Lip GYH
    Front Endocrinol (Lausanne); 2022; 13():975912. PubMed ID: 36187122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanding spectrum of mast cell activation disorders: monoclonal and idiopathic mast cell activation syndromes.
    Picard M; Giavina-Bianchi P; Mezzano V; Castells M
    Clin Ther; 2013 May; 35(5):548-62. PubMed ID: 23642289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenic and diagnostic relevance of KIT in primary mast cell activation disorders.
    Muñoz-González JI; García-Montero AC; Orfao A; Álvarez-Twose I
    Ann Allergy Asthma Immunol; 2021 Oct; 127(4):427-434. PubMed ID: 34298172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.